Jolanta Grembecka’s group was the first to synthesize small molecules targeting the KMT2A binding site in Menin to specifically inhibit this protein-protein interaction (Fig. 1) and demonstrated activity in KMT2A-rearranged leukemia models [38]. Here, KMT2A is linked to leukemia.